Can GastroPanel be used as a triage tool to select patients with advanced atrophic gastritis for gastroscopy? A prospective clinical validation study
Objective Gastric adenocarcinoma (GAC) is the 17th most common cancer in the UK with a 5-year survival rate of 22%. GastroPanel (Biohit Oyj; Helsinki, Finland) is an ELISA kit that measures pepsinogen I (PGI); pepsinogen II (PGII); gastrin-17 (G-17); and Helicobacter pylori IgG antibodies (Hp IgG)....
Saved in:
| Main Authors: | , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
BMJ Publishing Group
2025-01-01
|
| Series: | BMJ Open Gastroenterology |
| Online Access: | https://bmjopengastro.bmj.com/content/12/1/e001559.full |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1841556937008742400 |
|---|---|
| author | Eleanor Wood Marco Novelli Laura Marelli Roger Feakins Cinzia Papadia Ray Shidrawi Kari Juhani Syrjänen |
| author_facet | Eleanor Wood Marco Novelli Laura Marelli Roger Feakins Cinzia Papadia Ray Shidrawi Kari Juhani Syrjänen |
| author_sort | Eleanor Wood |
| collection | DOAJ |
| description | Objective Gastric adenocarcinoma (GAC) is the 17th most common cancer in the UK with a 5-year survival rate of 22%. GastroPanel (Biohit Oyj; Helsinki, Finland) is an ELISA kit that measures pepsinogen I (PGI); pepsinogen II (PGII); gastrin-17 (G-17); and Helicobacter pylori IgG antibodies (Hp IgG). PGI and the PGI/PGII ratio correlate inversely with the severity of chronic atrophic gastritis (AG). The aim of this study was to assess GastroPanel performance in the identification of moderate to severe AG in dyspepsia.Methods In this UK, single-centre, prospective diagnostic accuracy study, 324 patients [56.8% (n=184) female; median age 57 years (range 39–92 years)] were recruited for gastroscopy with biopsy and histology according to the updated Sydney System (USS). Blood (plasma) samples were collected for GastroPanel analysis. Paired samples were obtained from 268 patients [56.3% (n=151) female; median age=57 (range 39–92 years)]. GastroPanel results were interpreted using the GastroSoft app (Biohit).Results Overall agreement between GastroPanel and the USS classification was 90% (95% CI=86.7 to 93.8%), with a weighted kappa (κw) of 0.828 (95% CI=0.781 to 0.865). In receiver operating characteristics (ROC) curve analysis, using moderate/severe atrophic gastritis of the corpus (AGC2+) as the endpoint, AUC=0.840 (95% CI 0.630 to 1.000) and 0.960 (95% CI 0.907 to 1.000) for PGI and the PGI/PGII ratio, respectively.Conclusion GastroPanel is a reliable dyspepsia triage test distinguishing patients who can be safely treated conservatively from those with moderate to severe corpus atrophic gastritis at high risk of developing GAC. |
| format | Article |
| id | doaj-art-58412c9a412048eaa86195e6e6790553 |
| institution | Kabale University |
| issn | 2054-4774 |
| language | English |
| publishDate | 2025-01-01 |
| publisher | BMJ Publishing Group |
| record_format | Article |
| series | BMJ Open Gastroenterology |
| spelling | doaj-art-58412c9a412048eaa86195e6e67905532025-01-07T04:55:09ZengBMJ Publishing GroupBMJ Open Gastroenterology2054-47742025-01-0112110.1136/bmjgast-2024-001559Can GastroPanel be used as a triage tool to select patients with advanced atrophic gastritis for gastroscopy? A prospective clinical validation studyEleanor Wood0Marco Novelli1Laura Marelli2Roger Feakins3Cinzia Papadia4Ray Shidrawi5Kari Juhani Syrjänen6Homerton University Hospital NHS Foundation Trust, London, UKDepartment of Pathology, University College London, London, UKHomerton University Hospital NHS Foundation Trust, London, UKDepartment of Pathology, University College London, London, UKGastroenterology, Barts Health Trust, London, UKGastroenterology, Homerton University Hospital, London, UKMedicine, University of Oulu Cancer and Translational Medicine Research Unit, Oulu, FinlandObjective Gastric adenocarcinoma (GAC) is the 17th most common cancer in the UK with a 5-year survival rate of 22%. GastroPanel (Biohit Oyj; Helsinki, Finland) is an ELISA kit that measures pepsinogen I (PGI); pepsinogen II (PGII); gastrin-17 (G-17); and Helicobacter pylori IgG antibodies (Hp IgG). PGI and the PGI/PGII ratio correlate inversely with the severity of chronic atrophic gastritis (AG). The aim of this study was to assess GastroPanel performance in the identification of moderate to severe AG in dyspepsia.Methods In this UK, single-centre, prospective diagnostic accuracy study, 324 patients [56.8% (n=184) female; median age 57 years (range 39–92 years)] were recruited for gastroscopy with biopsy and histology according to the updated Sydney System (USS). Blood (plasma) samples were collected for GastroPanel analysis. Paired samples were obtained from 268 patients [56.3% (n=151) female; median age=57 (range 39–92 years)]. GastroPanel results were interpreted using the GastroSoft app (Biohit).Results Overall agreement between GastroPanel and the USS classification was 90% (95% CI=86.7 to 93.8%), with a weighted kappa (κw) of 0.828 (95% CI=0.781 to 0.865). In receiver operating characteristics (ROC) curve analysis, using moderate/severe atrophic gastritis of the corpus (AGC2+) as the endpoint, AUC=0.840 (95% CI 0.630 to 1.000) and 0.960 (95% CI 0.907 to 1.000) for PGI and the PGI/PGII ratio, respectively.Conclusion GastroPanel is a reliable dyspepsia triage test distinguishing patients who can be safely treated conservatively from those with moderate to severe corpus atrophic gastritis at high risk of developing GAC.https://bmjopengastro.bmj.com/content/12/1/e001559.full |
| spellingShingle | Eleanor Wood Marco Novelli Laura Marelli Roger Feakins Cinzia Papadia Ray Shidrawi Kari Juhani Syrjänen Can GastroPanel be used as a triage tool to select patients with advanced atrophic gastritis for gastroscopy? A prospective clinical validation study BMJ Open Gastroenterology |
| title | Can GastroPanel be used as a triage tool to select patients with advanced atrophic gastritis for gastroscopy? A prospective clinical validation study |
| title_full | Can GastroPanel be used as a triage tool to select patients with advanced atrophic gastritis for gastroscopy? A prospective clinical validation study |
| title_fullStr | Can GastroPanel be used as a triage tool to select patients with advanced atrophic gastritis for gastroscopy? A prospective clinical validation study |
| title_full_unstemmed | Can GastroPanel be used as a triage tool to select patients with advanced atrophic gastritis for gastroscopy? A prospective clinical validation study |
| title_short | Can GastroPanel be used as a triage tool to select patients with advanced atrophic gastritis for gastroscopy? A prospective clinical validation study |
| title_sort | can gastropanel be used as a triage tool to select patients with advanced atrophic gastritis for gastroscopy a prospective clinical validation study |
| url | https://bmjopengastro.bmj.com/content/12/1/e001559.full |
| work_keys_str_mv | AT eleanorwood cangastropanelbeusedasatriagetooltoselectpatientswithadvancedatrophicgastritisforgastroscopyaprospectiveclinicalvalidationstudy AT marconovelli cangastropanelbeusedasatriagetooltoselectpatientswithadvancedatrophicgastritisforgastroscopyaprospectiveclinicalvalidationstudy AT lauramarelli cangastropanelbeusedasatriagetooltoselectpatientswithadvancedatrophicgastritisforgastroscopyaprospectiveclinicalvalidationstudy AT rogerfeakins cangastropanelbeusedasatriagetooltoselectpatientswithadvancedatrophicgastritisforgastroscopyaprospectiveclinicalvalidationstudy AT cinziapapadia cangastropanelbeusedasatriagetooltoselectpatientswithadvancedatrophicgastritisforgastroscopyaprospectiveclinicalvalidationstudy AT rayshidrawi cangastropanelbeusedasatriagetooltoselectpatientswithadvancedatrophicgastritisforgastroscopyaprospectiveclinicalvalidationstudy AT karijuhanisyrjanen cangastropanelbeusedasatriagetooltoselectpatientswithadvancedatrophicgastritisforgastroscopyaprospectiveclinicalvalidationstudy |